eLQ vs SARCULATOR
Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.
eLQ
This medical app calculates biological equivalent doses for radiation therapy using the linear-quadratic model. It allows users to select various organs and α/β ratios for precise calculations.
- Linear-quadratic model calculations
- Selectable organs (spine, heart, lung, liver, skin)
- Adjustable α/β ratios
- Biological equivalent dose computation
Read full descriptionHide full description
eLQ calculates biological equivalent dose for radiation therapy treatment using the linear-quadratic model. Users can choose betweens organs (spine, heart, lung, liver, skin, ...) or several α/β ratios.
SARCULATOR
This medical tool provides physicians with predictive models for retroperitoneal and extremity sarcoma patients. It estimates overall survival and disease-free survival, serving as an informative resource to enhance physician predictive capabilities.
- Predictive models for sarcoma patients
- Estimates 5-year overall survival
- Estimates 5-year disease-free survival
- Estimates 10-year overall survival
- Estimates cumulative incidence of distant metastasis
- Informative tool for physicians
Read full descriptionHide full description
This app is meant to be used only by physicians and it is not meant to make clinical decisions (the clinical usefulness of the two models has not been tested) but to be used as an informative tool to improve the predictive capability of a physician. Two kinds of predictions are possible: - RPS: 5-year overall survival (OS) and 5-year disease-free survival (DFS) in primary resected retroperitoneal sarcoma (RPS) patients. . - ESTS: 5- and 10-year overall survival (OS) and cumulative incidence of distant metastasis (CCI of DM) in primary resected extremity STS patients.
Screenshots
Verdict
The clearest difference is rating: SARCULATOR at 4.3 against eLQ's 4.0. SARCULATOR also leads on update cadence (every 7 months vs every 14 months) and ratings volume (3 vs 1). eLQ's advantage is iOS requirement (6.0 vs 13.0). On price, ads, in-app purchases and monetization model there is nothing between them.
Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS
Both are free to download. Neither carries in-app purchases, so what you see is what you pay.
SARCULATOR holds the better App Store score, 4.3 against 4.0. Both are backed by a comparable volume of ratings — 1 and 3 respectively.
eLQ ships an update every 14 months, SARCULATOR every 7 months. The most recent releases landed on September 18, 2026 and September 21, 2026 respectively.
| Parameter | eLQ | SARCULATOR |
|---|---|---|
| Price | Free | Free |
| Rating | 4.0 (1 ratings) | 4.3 (3 ratings) — better |
| Positive reviews | 66.7% of reviews | — |
| Number of ratings | 1 | 3 — better |
| Update frequency | Every 14 months | Every 7 months — better |
| Ads | No | No |
| In-app purchases | No | No |
| Monetization | Free | Free |
| Devices | iPhone, iPad, iPod | iPhone, iPad, iPod |
| Requires iOS | 6.0 — better | 13.0 |
| Further details — not scored | ||
| Size | 12 MB | 26 MB |
| Age rating | 17+ | 12+ |
| Developer | SFjRO | DIGITAL FOREST SRL |
Customer experience
eLQ
SARCULATOR
In-app purchases
eLQ
No in-app purchases
SARCULATOR
No in-app purchases
